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Abstract The aim of this study
was to test genetic differences in
the clinical response to rizatriptan
in patients affected by migraine
without aura. These genetic differ-
ences could be explained by vari-
ous genes, the HTR1B, encoding
the 5-HT1 receptor subtype, MAO-
A gene that encodes the
monoamino-oxidase, the main
metabolic enzyme of this triptan,
SLC6A4 (gene encoding the sero-
tonin transporter) and DRD2 (gene
encoding the D2 receptor), both
involved in the pathogenesis of
migraine. Fifty unrelated patients
affected by migraine without aura
(IHS) were included. Patients were
divided into two groups (respon-
ders and non-responders) accord-
ing to clinical response. Thirty-one
out of fifty patients responded to
rizatriptan. A significant difference
among the two groups was
observed in both allele (p=0.02)
and genotype distribution (p=0.03)
of DRD2/NcoI. The significant
association with the DRD2/NcoI
polymorphism in responders sug-
gested that the DRD2/NcoI C
allele may be considered a suscep-
tibility factor heralding a good
response to rizatriptan.
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Migraine is a complex genetic disease, wherein suscepti-
bility genes and environmental factors both contribute to
its development. Moderate to severe migraine attacks are
usually treated with triptans, specific anti-migraine drugs.
Nevertheless, up to 15% of migraineurs fail to respond to
triptans. As multiple clinical and genetic factors may con-
tribute towards inter-patient difference in the clinical
response to drugs, several studies have been performed to
characterise the response and non-response to triptans [1].
Rizatriptan is a 5-HT1B receptor agonist, which has
proved to be considerably efficient in treating migraine
attacks [2]. Genetic differences in the clinical response to
rizatriptan could be explained by various genes, namely
the one encoding the 5-HT1 receptor subtype (HTR1B
gene), representing the pharmacological target of the drug,
and that encoding the monoamino-oxidase (MAO-A gene),
the main metabolic enzyme of this triptan.
The pathogenesis of migraine is not yet fully under-
stood but both neural and vascular mechanisms are known
to be involved [3, 4]; moreover, an altered monoaminergic
neurotransmission has also been implicated, particularly of
serotonergic and, more recently, dopaminergic systems
[5]. In this regard, some authors have reported an associa-
tion between migraine and the gene of D2 dopaminergic
receptors [6, 7].
When undertaking studies of pharmacogenetics, it
would be advisable to also consider genes related to the
pathogenesis of the disease as possible candidates. Indeed,
should the drug prove to be clinically effective, it is rea-
sonable to hypothesise that it will affect key mechanisms,
although not in a direct manner.
Thus, we designed a prospective study to test the
hypothesis that genetic variation might be one of the fac-
tors responsible for the resistance to therapy observed in
patients affected by migraine without aura (MOA) treated
with rizatriptan. In our sample we carried out an associa-
tion study with the HTR1B, the MAO-A and the DRD2
genes. We chose the polymorphisms on the basis of a
hypothesised functional role or on the basis of already pos-
itive association studies with migraine.
Methods
Patients
Fifty unrelated male and female patients (45 women, 5 men; age
19–50 years), all Sardinian, affected by MOA (IHS criteria), consec-
utively admitted to our Headache Centre (HC), were included in the
study. The length of the study was one and a half years. Symptomatic
headaches were excluded by clinical examination, Doppler sonogra-
phy and, when necessary, by CT scan or MRI. A direct interview was
conducted by the physicians of the HC with experience in headache
diagnosis. Clinical and demographic data of each patient were col-
lected. Familiarity was evaluated only on the first degree relatives.
The patients filled in a diary reporting the following features: number
and duration of migraine attacks, intensity of migraine on the usual
4-step scale: 0, none; 1, mild; 2, moderate; 3, severe headache; pres-
ence of associated symptoms; number of rescue medications request-
ed (rizatriptan 10 mg); need for rescue medications other than the
selected triptan. Response and non-response for each patient were
estimated using data recorded in the diary. Migraineurs were eligible
for inclusion only if they had treated at least five migraine attacks
with 10 mg oral rizatriptan. The study was carried out in accordance
with the Declaration of Helsinki and was approved by the local Ethics
Committee. Informed consent was obtained from all subjects before
participation in the study.
The patients were divided into two groups (responders and
non-responders) according to their clinical response to 10 mg
oral rizatriptan. Clinical response was defined as being pain-free
within two hours of rizatriptan intake according to IHS
Guidelines.
Patients who were pain-free within two hours after 10 mg
oral rizatriptan in at least four out of five migraine attacks were
defined as “responders”. Patients who were not pain-free in at
least three of five consecutively treated migraine attacks were
defined as “non-responders” [8]. Patients with partial response to
rizatriptan were excluded from genotyping.
Genotyping
High-molecular weight genomic DNA was extracted from
peripheral blood leukocytes according to standard procedures.
D2 receptor gene (DRD2) polymorphisms
Polymerase chain reaction (PCR) and NcoI restriction fragment
length polymorphism (RFLP)
The silent C/T transition (His313His) located in exon 6 was
analysed according to the method of Sarkar et al. [9]. PCR prod-
ucts, a 446-bp fragment, were digested with NcoI restriction
enzyme. Digested products were separated on 1.5% agarose gel.
The restriction profiles were visualised by ethidium bromide
staining.
PCR and BstNI RFLP
The -141 C Ins/Del variant in the promoter region of the DRD2
was analysed according to Arinami et al. [10]. The PCR products,
a 304-bp (insertion variant) or 303-bp fragment (deletion vari-
ant), were digested with restriction enzyme BstN I (BioLabs).
Alleles were resolved by a 2% agarose gel electrophoresis and
were visualised by ethidium bromide staining.
Serotonin transporter gene (SLC6A4)
Insertion/deletion polymorphism in the 5' promoter region of the
SLC6A4 was detected according to the method described by
Lesch et al. [11]. PCR products were separated on 2% agarose
gels supplemented with ethidium bromide allowing differentia-
tion of the long (528 bp) and short (484 bp) variant.
5-HT1Dβ
A silent mutation substitution at nucleotide 861 of the coding
region was detected by PCR-based HincII restriction digestion
assay according to Lappalainen et al. [12]. The PCR product, a
fragment of 548 bp, was digested with the restriction enzyme
HincII and the digested products were separated on 2% agarose
gels supplemented with ethidium bromide allowing differentia-
tion of the G (452 bp and 96 bp) and C (309 bp and 143 bp)
allele.
MAO-A
The determination of the polymorphism for EcoRV in MAO-A
gene was performed according to Hotamisligil and Breakefield
[13]. A 488-bp fragment indicates the presence of N allele (N=no
EcoRV restriction site) and a 456-bp fragment indicates the pres-
ence of Y allele (Y=presence of EcoRV restriction site).
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Genotypes were scored independently by two experienced inves-
tigators unaware of the clinical data. Differences were resolved
by repeating the typing of the individual in question.
Statistical analysis
Deviation from the genotype counts predicted by Hardy-
Weinberg equilibrium expectations was tested using HWE pro-
gram [14]. Fisher’s exact test was used to compare allelic fre-
quencies. Variation in genotype frequencies was tested by 2x3χ2
contingency table analysis. We used the CLUMP_New [15] pro-
gram to estimate empirical significance values of the χ2 statistic
(T1) using 10 000 Monte Carlo simulations. We applied data with
non-corrected p values as the appropriate correction for non-
independent multiple testing is controversial for genetic studies
of complex diseases.
When multiple tests are performed, an increased rate of type I
errors should be anticipated but, in an exploratory design, a cor-
rection might unacceptably inflate the number of type II errors.
Results
Demographic and clinical data of the 50 patients affected by
MOA included in the study are shown in Table 1. Thirty-one
out of fifty patients (62%) were considered good responders
to rizatriptan. There were 13 non-responders (26%). Six
patients (5 women+1 man) were partial responders to riza-
triptan, thus they were not genotyped. The two genotyped
patient groups did not differ significantly in the items stud-
ied. The percentage of patients with associated symptoms
such as nausea and vomiting were similar in both responder
and non-responder groups (Table 2).
The genotypic counts were in Hardy-Weinberg equilibri-
um in rizatriptan responders and non-responders at these
polymorphic loci.
No significant differences were observed in allele and
genotype frequencies of HTR1B, MAO-A, SLC6A4 and
DRD2/BstNI polymorphisms (Table 3).
As shown in Table 4, allele distribution of DRD2 was
significantly different in responders and non-responders
(p=0.02, OR=3.68, 95% CI: 1.27–10.62). Genotype distri-
bution among the two groups also differed significantly
(χ2=6.21, df=2, p=0.03).
Discussion
The cumulative data obtained with the trials of rizatriptan
as well as with reports from clinical practice make riza-
triptan 10 mg an indicated oral triptan for migraine
patients. However, despite its effectiveness, the use of trip-
tans does not result in complete relief of migraine in all
patients. However, response to treatment is difficult to
define, in view of the variability of individual responses to
any pharmacologic treatments in migraineurs, representing
a troublesome obstacle for general interpretation. In the
absence of encoding definition criteria for responders and
non-responders to triptans in the literature, we have chosen
the definition of response as at least 4 successful treat-
ments with 10 mg rizatriptan in five attacks [1, 16], as it
has proved the most reliable to date.
A total of 62% responders to rizatriptan were evi-
denced, similar to data already published [2].
In the present study, allele frequencies in the HTR1B,
MAO-A and DRD2/BstNI polymorphisms did not differ
between responders and non-responders. These negative
results are not very meaningful due to the relatively small
size of our sample and a gene that has minor contribution

















Frequency of attacks (#/month)
Mean±SD 3.8±2.7
Median 3
Length of attacks in hours 
Mean±SD 48±18.8
Median* 48
Intensity of attacks (# of patients)
Moderate 36 (72%)
Severe 14 (28%)
Nausea (no. of patients) 48 (96%)
Vomiting (no. of patients) 33 (66%)
Phonophobia (no. of patients) 40 (80%)
Photophobia (no. of patients) 40 (80%)
Intolerance to movement (no. of patients) 42 (84%)
Yawning (no. of patients) 13 (26%)
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could not be detected. Moreover, other authors have shown
negative results on association studies between migraine
and the genes of 5-HT1B and 5-HT1F [16, 17].
A significant association in allelic frequency of the
DRD2/NcoI polymorphism was found in responders to
rizatriptan. In fact, a significant increase is observed in the
frequency for the C allele among responders compared to
non-responders, suggesting that this allele may be consid-
ered a susceptibility factor heralding a good response to
rizatriptan. This polymorphism is a silent mutation and may
serve as an associated marker through linkage disequilibri-
um with other functional mutations. In the present study,
we speculate that the C allele may be in linkage disequilib-
rium with other functional mutations in the DRD2 gene.
The role of the dopaminergic system in migraine has
also been suggested on the basis of genetic evidence. It has
recently been suggested that genetic variations within the
dopaminergic system may underlie clinical susceptibility
to migraine, although additional genetic, biochemical and
clinical studies should be undertaken [18]. In this regard,
findings reported by basic studies may be of interest. The
Table 2 Demographic and clinical characteristics of responder (R)
and non-responder (NR) patients to rizatriptan
R (#31) NR (#13)
Age 











Frequency of attacks (#/month)
Mean±SD 3.8±3 3.4±1.7
Median* 3 3
Length of attacks in hours 
Mean±SD 45.3±17.2 54.5±21.2
Median* 48 72
Intensity of attacks (# of patients)**
Moderate 24 (77%) 8 (62%)
Severe 7 (23%) 5 (38%)
Nausea (no. of patients)** 31 (71%) 11 (85%)
Vomiting (no. of patients)** 22 (71%) 5 (38%)
Phonophobia (no. of patients)** 23 (74%) 12 (92%)
Photophobia (no. of patients)** 23 (74%) 12 (92%)
Intolerance to movement ** 24 (77%) 13 (100%)
(no. of patients)
Yawning (no. of patients)** 9 (29%) 2 (15%)
* non significant p>0.05 Mann-Whitney test
** non significant p>0.05 χ2
Table 3 Genotype and allele frequencies of SLC6A4, 5-HT1Dβ
MAO-A and DRD2/BstNI polymorphisms in rizatriptan-respon-
sive and non-responsive individuals
Genotype Allele
SLC6A4 ll ls ss l s
Responder (#31) 11 14 6 36 26
Non-responder (#13) 6 5 2 17 9
χ2=2.87; p=0.26; p=0.63
Genotype Allele
5-HT1Dβ GG GC CC G C
Responder (#31) 21 9 1 51 11
Non-responder (#13) 11 2 0 24 2
χ2=1.46; p=0.61; p=0.32
Genotype Allele
MAO-A NN NY YY N Y
Responder (#29) 19 8 2 46 12
Non-responder (#11) 6 3 2 15 7
χ2= 2; p=0.67; p=0.39
Genotype Allele
DRD2/BstNI II ID DD I D
Responder (#31) 28 3 0 59 3
Non-responder (#13) 13 0 0 26 0
χ2= 1.352; p=0.55; p=0.55
Table 4 DRD2/NcoI allele and genotype frequency
Allele Genotype
C T CC CT TT
Responder 53 (0.85) 9 (0.15) 24 (0.77)5 (0.16)2 (0.07) 
(#31)
Non-responder 16 (0.62) 10 (0.38) 5 (0.38)6 (0.46)2 (0.16) 
(#13)
p=0.02 Fisher’s exact test χ2=6.21; p=0.03; 
O.R.=3.68, 95% C.I.=1.27–10.62
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dopaminergic system has been implicated in the regulation
of cerebral cortical microcirculation and disturbances in
central dopaminergic neurotransmission have been shown
to alter cerebrovascular regulation and blood–brain barrier
permeability [19]. Moreover, it has been reported that
dopamine strongly and selectively inhibits the vascular
permeability and the angiogenic activities of permeability
factor/vascular endothelial growth factor (VPF/VEGF),
acting through the D2 receptors [20].
The data show that the genotype and allele frequencies
for the DRD2/NcoI polymorphism differ between the
responder and non-responder groups we studied (p=0.03,
p=0.02). This preliminary study provides some evidence
that the DRD2 variant is associated with clinical response
to rizatriptan. In conclusion, in spite of the small size of
the sample examined and the need of replication in other
types of populations, this study underlines the possible
usefulness of a pharmacogenetic strategy as a tool to study
potential drug targets.
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